SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,083,584 | +166.4% | 39,303 | +190.5% | 0.00% | 0.0% |
| Q2 2023 | $406,712 | -55.1% | 13,530 | -45.9% | 0.00% | 0.0% |
| Q1 2023 | $906,221 | +47.4% | 25,013 | +45.1% | 0.00% | 0.0% |
| Q4 2022 | $614,951 | -99.9% | 17,240 | -25.9% | 0.00% | 0.0% |
| Q2 2022 | $672,737,000 | +20.0% | 23,262 | +34.1% | 0.00% | 0.0% |
| Q1 2022 | $560,461,000 | -68.2% | 17,341 | -71.3% | 0.00% | -66.7% |
| Q4 2021 | $1,764,763,000 | +21.2% | 60,520 | +10.9% | 0.00% | +50.0% |
| Q3 2021 | $1,455,649,000 | +97.4% | 54,580 | +127.9% | 0.00% | +100.0% |
| Q2 2021 | $737,513,000 | +22.9% | 23,953 | +4.5% | 0.00% | 0.0% |
| Q1 2021 | $599,862,000 | +48.1% | 22,913 | +42.3% | 0.00% | 0.0% |
| Q4 2020 | $405,076,000 | +41.9% | 16,100 | +17.5% | 0.00% | – |
| Q3 2020 | $285,550,000 | -55.1% | 13,702 | -48.9% | 0.00% | -100.0% |
| Q2 2020 | $636,548,000 | -71.9% | 26,802 | -78.7% | 0.00% | -80.0% |
| Q1 2020 | $2,264,149,000 | +663.7% | 125,856 | +906.9% | 0.01% | +400.0% |
| Q4 2019 | $296,476,000 | +20.6% | 12,499 | +39.7% | 0.00% | – |
| Q3 2019 | $245,781,000 | +12.9% | 8,944 | +36.0% | 0.00% | – |
| Q2 2019 | $217,633,000 | -45.3% | 6,577 | -42.0% | 0.00% | -100.0% |
| Q1 2019 | $397,529,000 | +923.7% | 11,345 | +870.5% | 0.00% | – |
| Q4 2018 | $38,834,000 | -79.2% | 1,169 | -68.4% | 0.00% | – |
| Q3 2018 | $186,345,000 | -62.4% | 3,701 | -55.2% | 0.00% | -100.0% |
| Q2 2018 | $494,960,000 | -45.0% | 8,270 | -57.9% | 0.00% | -50.0% |
| Q1 2018 | $900,336,000 | +9.3% | 19,658 | -4.9% | 0.00% | +100.0% |
| Q4 2017 | $823,460,000 | -21.0% | 20,664 | -20.7% | 0.00% | -66.7% |
| Q3 2017 | $1,042,880,000 | +60.9% | 26,072 | +73.4% | 0.00% | +50.0% |
| Q2 2017 | $647,965,000 | -85.1% | 15,034 | -89.2% | 0.00% | -81.8% |
| Q1 2017 | $4,343,188,000 | +1592.7% | 138,760 | +1265.5% | 0.01% | +1000.0% |
| Q4 2016 | $256,591,000 | +51.3% | 10,162 | +48.2% | 0.00% | 0.0% |
| Q3 2016 | $169,598,000 | -27.5% | 6,858 | -40.3% | 0.00% | 0.0% |
| Q2 2016 | $233,807,000 | +202.3% | 11,478 | +126.3% | 0.00% | – |
| Q1 2016 | $77,333,000 | -19.6% | 5,071 | -29.1% | 0.00% | – |
| Q4 2015 | $96,150,000 | -12.4% | 7,154 | -8.6% | 0.00% | – |
| Q3 2015 | $109,813,000 | +126.3% | 7,827 | +173.9% | 0.00% | – |
| Q2 2015 | $48,529,000 | +489.4% | 2,858 | +319.7% | 0.00% | – |
| Q1 2015 | $8,233,000 | -57.9% | 681 | -69.7% | 0.00% | – |
| Q3 2014 | $19,535,000 | +3737.9% | 2,248 | +3525.8% | 0.00% | – |
| Q1 2014 | $509,000 | -66.2% | 62 | -69.0% | 0.00% | – |
| Q4 2013 | $1,508,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |